ClinicalTrials.gg
CompletedNCT02298192DUAL™ VIUpdated May 23, 2017Results posted

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

A Phase 3 interventional study of insulin degludec/liraglutide in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 84 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-23.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
31st of 70
420 · median 384
Started
2014
with 2 others
Phase 3
49 of 70
2 open now
Registered
42nd of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 31st largest by enrollment, is one of 3 that started in 2014, is one of 49 in phase 3, and was the 42nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Europe, North America and the United States of America.

The aim of this trial is to compare two different titration algorithms of insulin degludec/liraglutide.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 420 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus
  • Male or female equal to or above 18 years of age
  • (glycosylated ) 7.0 - 10.0% [53 mmol/mol - 86 mmol/mol] (both inclusive), confirmed by the central laboratory
  • Stable daily treatment with metformin (above or equal to 1500 mg or max tolerated dose) with or without pioglitazone (above orequal to 30 mg) for at least 90 days prior to screening
  • (BMI) below or equal to 40 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Current use of any anti-diabetic drugs (except for metformin and pioglitazone) or anticipated change in concomitant medication, which, in the opinion of the investigator, could interfere with the glucose metabolism (e.g. systemic )
  • Previous and / or current treatment with insulin (short term treatment due to intercurrent illness, including gestational diabetes, is allowed at the discretion of the investigator)
  • Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, sulpfonylurea, glinides, dipeptidyl peptidase 4 (DPP-4) inhibitors or sodium-glucose co-transporter 2 (SGLT2) inhibitors within 90 days prior to the screening visit
  • Impaired liver function, defined as (ALAT) above or equal to 2.5 times upper normal range (UNR)
  • Impaired renal function defined as serum-creatinine above or equal to 133 micromol/L (above or equal to 1.5 mg/dL) for males and above or equal to 125 micromol/L (above or equal to 1.4 mg/dL) for females, or as defined according to local for metformin
  • Screening calcitonin above or equal to 50 ng/L
  • Proliferative retinopathy or maculopathy (macular oedema) requiring acute treatment, according to investigator's clinical judgment
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
  • History of pancreatitis (acute or chronic)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
420 participants (actual)

Study arms

  • Experimental
    Once weekly titration

    Drug: insulin degludec/liraglutide

  • Experimental
    Twice weekly titration

    Drug: insulin degludec/liraglutide

Interventions

  • Druginsulin degludec/liraglutide

    Drug pages: Insulin degludec · Liraglutide

    For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c

    Change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline after 32 weeks of treatment.

    Time frame: Week 0, week 32

Secondary outcomes

  1. HbA1c Below 7.0%

    Responders to HbA1c below 7% after 32 weeks of treatment.

    Time frame: Week 0, week 32

  2. HbA1c Below or Equal to 6.5%

    Responders to HbA1c below or equal to 6.5% after 32 weeks of treatment.

    Time frame: Week 0, week 32

  3. Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes

    An episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

    Time frame: Week 0-32

08

Results

Posted May 23, 2017

Participant flow

The trial was conducted at 80 sites in 9 countries as follows:Austria: 6 sites; Bulgaria: 5 sites; Canada: 7 sites, Czech Republic:5 sites; Hungary: 4 sites, Russian Federation: 6 sites; Serbia: 4sites, Slovakia: 7 sites; United States: 36 sites.

Participant flow — Overall Study
MilestoneIDegLira (1WT)IDegLira
Started210210
Completed191204
Not completed196
Withdrew: Unclassified32
Withdrew: Withdrawal criteria20
Withdrew: Withdrawal by subject61
Withdrew: Lost to follow-up21
Withdrew: Adverse event62

Outcome measures

PrimaryChange From Baseline in HbA1c

Change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline after 32 weeks of treatment.

Time frame:
Week 0, week 32
Reported as:
Mean · percentage
Change From Baseline in HbA1c
percentageIDegLira (1WT)IDegLira
Change From Baseline in HbA1c-2.01 ± 1.09-2.02 ± 0.98
Statistical analysis
  • IDegLira (1WT) vs IDegLira · Mixed Models Analysis · p = 0.012 · Treatment contrast: 0.12 · 95% CI -0.04 to 0.28
SecondaryHbA1c Below 7.0%

Responders to HbA1c below 7% after 32 weeks of treatment.

Time frame:
Week 0, week 32
Reported as:
Number · participants
HbA1c Below 7.0%
participantsIDegLira (1WT)IDegLira
yes170179
No1921
SecondaryHbA1c Below or Equal to 6.5%

Responders to HbA1c below or equal to 6.5% after 32 weeks of treatment.

Time frame:
Week 0, week 32
Reported as:
Number · particpants
HbA1c Below or Equal to 6.5%
particpantsIDegLira (1WT)IDegLira
yes158170
No3130
SecondaryNumber of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes

An episode that is severe according to the ADA classification or BG confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

Time frame:
Week 0-32
Reported as:
Number · Number of episodes
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes
Number of episodesIDegLira (1WT)IDegLira
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes2097

Adverse events

Collected over Defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than seven days after the last day of randomised treatment. (Visit 1- Visit 36). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDegLira (1WT)—7/209 (3.3%)24/209 (11.5%)
IDegLira—14/210 (6.7%)19/210 (9%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventIDegLira (1WT)IDegLira
AppendicitisInfections and infestations0/2092/210
NephrolithiasisRenal and urinary disorders0/2092/210
ColitisGastrointestinal disorders1/2090/210
Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2090/210
EnteritisGastrointestinal disorders1/2090/210
HyperglycaemiaMetabolism and nutrition disorders1/2090/210
HypotensionVascular disorders1/2090/210
MigraineNervous system disorders1/2090/210
Non-cardiac chest painGeneral disorders1/2090/210
Peripheral arterial occlusive diseaseVascular disorders1/2090/210
Most frequent other events
Most frequent other events
EventIDegLira (1WT)IDegLira
NasopharyngitisInfections and infestations13/2099/210
NauseaGastrointestinal disorders11/20911/210

Baseline characteristics

Full analysis set (FAS): Included all randomised subjects. The subjects in IDegLira (IWT) and IDegLira are 210 in each arm.

Age, Continuous
Age, Continuous(years)IDegLira (1WT)IDegLiraTotal
Mean56.6 ± 10.357.0 ± 9.656.8 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)IDegLira (1WT)IDegLiraTotal
Female9998197
Male111112223
HbA1c
HbA1c(percentage)IDegLira (1WT)IDegLiraTotal
Mean8.2 ± 0.98.1 ± 0.98.1 ± 0.9
09

Study locations

84 sites
  • Novo Nordisk Investigational Site
    Hamilton, Alabama 35570, United States
  • Novo Nordisk Investigational Site
    Chandler, Arizona 85224, United States
  • Novo Nordisk Investigational Site
    Glendale, Arizona 85306-4652, United States
  • Novo Nordisk Investigational Site
    Glendale, Arizona 85308, United States
  • Novo Nordisk Investigational Site
    Mesa, Arizona 85213, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85018, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85020, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85741, United States
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    Palm Springs, California 92262, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80904, United States
  • Novo Nordisk Investigational Site
    Boynton Beach, Florida 33472, United States
  • Novo Nordisk Investigational Site
    Clearwater, Florida 33765, United States
  • Novo Nordisk Investigational Site
    Hallandale Beach, Florida 33009, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33173, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32801, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33603, United States
  • Novo Nordisk Investigational Site
    Conyers, Georgia 30094-5965, United States
  • Novo Nordisk Investigational Site
    Blackfoot, Idaho 83221, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46254, United States
  • Novo Nordisk Investigational Site
    Crestview Hills, Kentucky 41017-3464, United States
  • Novo Nordisk Investigational Site
    Troy, Michigan 48098, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89103, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    West Seneca, New York 14224, United States
  • Novo Nordisk Investigational Site
    Greensboro, North Carolina 27408, United States
  • Novo Nordisk Investigational Site
    Norman, Oklahoma 73069, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Novo Nordisk Investigational Site
    Greer, South Carolina 29651, United States
  • Novo Nordisk Investigational Site
    Spartanburg, South Carolina 29303, United States
  • Novo Nordisk Investigational Site
    Humboldt, Tennessee 38343, United States
  • Novo Nordisk Investigational Site
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77008, United States
  • Novo Nordisk Investigational Site
    Katy, Texas 77450, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78215, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78240, United States
  • Novo Nordisk Investigational Site
    Newport News, Virginia 23606, United States
  • Novo Nordisk Investigational Site
    Richmond, Virginia 23294, United States
  • Novo Nordisk Investigational Site
    Linz, 4021, Austria
  • Novo Nordisk Investigational Site
    Mödling, 2340, Austria
  • Novo Nordisk Investigational Site
    St. Stefan, 8511, Austria
  • Novo Nordisk Investigational Site
    Wien, 1010, Austria
  • Novo Nordisk Investigational Site
    Wien, 1090, Austria
  • Novo Nordisk Investigational Site
    Wien, 1130, Austria
  • Novo Nordisk Investigational Site
    Wien, 1230, Austria
  • Novo Nordisk Investigational Site
    Kozloduy, 3320, Bulgaria
  • Novo Nordisk Investigational Site
    Lukovit, 5770, Bulgaria
  • Novo Nordisk Investigational Site
    Ruse, 7000, Bulgaria
  • Novo Nordisk Investigational Site
    Sofia, 1784, Bulgaria
  • Novo Nordisk Investigational Site
    Varna, 9002, Bulgaria
  • Novo Nordisk Investigational Site
    Burnaby, British Columbia V5G 1T4, Canada
  • Novo Nordisk Investigational Site
    Coquitlam, British Columbia V3K 3P4, Canada
  • Novo Nordisk Investigational Site
    Surrey, British Columbia V3S 2N6, Canada
  • Novo Nordisk Investigational Site
    Moncton, New Brunswick E1G 1A7, Canada
  • Novo Nordisk Investigational Site
    Halifax, Nova Scotia B3K 2M5, Canada
  • Novo Nordisk Investigational Site
    Liverpool, Nova Scotia B0T 1K0, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N6G 2M1, Canada
  • Novo Nordisk Investigational Site
    Waterloo, Ontario N2J 1C4, Canada
  • Novo Nordisk Investigational Site
    Olomouc, Lazce, 77900, Czechia
  • Novo Nordisk Investigational Site
    Plzen, 30166, Czechia
  • Novo Nordisk Investigational Site
    Plzen, 32600, Czechia
  • Novo Nordisk Investigational Site
    Praha 4, 140 46, Czechia
  • Novo Nordisk Investigational Site
    Trutnov, 541 01, Czechia
  • Novo Nordisk Investigational Site
    Budapest, 1089, Hungary
  • Novo Nordisk Investigational Site
    Budapest, 1135, Hungary
  • Novo Nordisk Investigational Site
    Debrecen, 4043, Hungary
  • Novo Nordisk Investigational Site
    Szombathely, H-9700, Hungary
  • Novo Nordisk Investigational Site
    Zalaegerszeg, 8900, Hungary
  • Novo Nordisk Investigational Site
    Barnaul, 656024, Russian Federation
  • Novo Nordisk Investigational Site
    Barnaul, 656045, Russian Federation
  • Novo Nordisk Investigational Site
    Cheboksary, 428000, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 194358, Russian Federation
  • Novo Nordisk Investigational Site
    Samara, 443041, Russian Federation
  • Novo Nordisk Investigational Site
    St. Petersburg, 194354, Russian Federation
  • Novo Nordisk Investigational Site
    Belgrade, 11000, Serbia
  • Novo Nordisk Investigational Site
    Bratislava, 81108, Slovakia
  • Novo Nordisk Investigational Site
    Bratislava, 82102, Slovakia
  • Novo Nordisk Investigational Site
    Bratislava, 851 01, Slovakia
  • Novo Nordisk Investigational Site
    Dunajska Streda, 92901, Slovakia
  • Novo Nordisk Investigational Site
    Sabinov, 08301, Slovakia
  • Novo Nordisk Investigational Site
    Vranov nad Toplou, 09301, Slovakia
  • Novo Nordisk Investigational Site
    Zilina, 01207, Slovakia
10

References and documents

Publications

  • Safety and Efficacy of Insulin Degludec/Liraglutide(IDegLira) Titrated Once Weekly (1 Wk) vs. Twice Weekly (2 Wk) in Patients (pts) with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study; Stewart B. Harris et al. American Diabetes Association - 76th Annual Scientific Sessions; 10 June 2016
  • Harris SB, Kocsis G, Prager R, Ridge T, Chandarana K, Halladin N, Jabbour S. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab. 2017 Jun;19(6):858-865. doi: 10.1111/dom.12892. Epub 2017 Mar 3. PubMed 28124817 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Dec 2015, 13 months.

Results were first posted in May 2017, 1 year 5 months after primary completion. A results delay was requested in Dec 2016.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2014
First posted
Nov 21, 2014
StartActual
Nov 21, 2014
Primary completionActual
Dec 23, 2015
CompletionActual
Dec 23, 2015
Results delay requested
Dec 6, 2016
Results first posted
May 23, 2017
Last update
May 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02298192
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 21, 2014
Start date
Nov 21, 2014
Primary completion
Dec 23, 2015
Completion
Dec 23, 2015
Results posted
May 23, 2017
Last update
May 23, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion